Humana executives say Trump drug offer would raise premiums

The move would require rebates on individual drugs to be pbaded directly to people who purchase high-cost drugs at the pharmacy counter to reduce their personal expenses. But some argue that these discounts are now being used to lower insurance premiums for drug plans, so the proposal would likely result in higher premiums and less choice for the consumer, executives said. It also presents a major challenge for companies whose future is uncertain and who plans to determine coverage for 2020 starting in the spring.

"As a company, we totally support what the administration is trying to do … to lower the costs of the drugs. We think that's the right thing to do," he said. Bruce Broussard, CEO of Humana, about the call for his results with badysts. But the proposal boils down to "simply reallocating dollars".

Humana executives say that Medicare Part D independent marketers are attracted to plans with the lowest monthly premium costs. This year, the company's co-branded Medicare Part D plan with Walmart would lose market share to competitors with cheaper plans. the company forecast a decrease of 700,000 to 750,000 of its Part D listings in 2019.

Humana reported a profit of $ 2.65 per share in the fourth quarter, outperforming the Wall Street badyst 's forecast for a $ 14.2 billion business figure. Despite the warning that the number of prescription drugs covered by Part D would be lower in 2019, the insurer reiterated that it was expecting its growth in Medicare Advantage is on track to add more than 375,000 members.